Pharmacist Impact In CML: Advancing Access and Frontline Treatment Decisions

Carmen Janes, PharmD, BCOP discusses how NCCN guidelines inform first-line CML treatment selection among TKIs like imatinib, nilotinib, and asciminib, emphasizing the importance of early molecular milestone achievement, proactive toxicity management, and the expanding role of pharmacists in optimizing patient adherence and quality of life through remote monitoring and medication access support.